Good and poor CD34+ cells mobilization in acute leukemia: analysis of factors affecting the yield of progenitor cells.
The factors possibly affecting the collection of peripheral blood stem cells (PBSC) were evaluated in 104 de novo acute leukemia patients (66 myeloid and 38 lymphoblastic leukemias) in first cytological complete remission (CR); all patients achieved CR after first-line induction chemotherapy. The acute myeloid leukemia patients (AML) were given consolidation-mobilization chemotherapy with cytarabine, and daunoblastin or mitoxantrone or idarubicin; the acute lymphoblastic leukemia patients (ALL) were given consolidation-mobilization chemotherapy with cytarabine and etoposide. In all patients, the collection of PBSC was performed during recovery after giving consolidation chemotherapy and granulocyte colony-stimulating factor (G-CSF). Two main groups were considered according to the CD34+ cells x 10(6)/kg b.w. collected, that is, poor mobilizers (PM), with a collection of <2 x 10(6)/kg and good mobilizers, with a collection of >2 x 10(6)/kg. Of 104 patients, 27 (25.9%) were PM; 20/27 had AML and 7/27 had ALL. At multivariate analysis, a lower CD34+ cells count premobilization chemotherapy (CD34 steady state), the presence of FUO (fever of unknown origin) or infection, and a lower number of CD34+ cells on the first day of collection correlated with poor mobilization. These results may enable early recognition of patients who may have poor mobilization, and aid selection of patients for different mobilization regimens.
Pastore
D
D
Hematology Section, Department DIMIMP, University of Bari, Italy. emadhba@cimedoc.uniba.it
Specchia
G
G
Mestice
A
A
Liso
A
A
Pannunzio
A
A
Carluccio
P
P
Buquicchio
C
C
Greco
G
G
Ciuffreda
L
L
Pietrantuono
G
G
Liso
V
V
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D018952:Antigens, CD34 / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002452:Cell Count; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods / Q000592:standards*; D006412:Hematopoietic Stem Cells; D006801:Humans; D007937:Leukapheresis / Q000592:standards; D007938:Leukemia / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D012307:Risk Factors
D018952:Antigens, CD34